3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
79
Phase 3
61
Phase NA
39
Phase 1
19
Phase 1/2
10
Phase EARLY_PHASE1
3
Phase 4
2
Status
Completed
2
Sponsor Class
OTHER
1
INDUSTRY
1
Study Type
Interventional
2
Sponsor
Cancer Type
Thoracic
3
Lymphoid
3
Gastrointestinal
3
Head & Neck
2
Genitourinary
2
Classical hematology
2
Breast
2
Tumor-Agnostic
1
Sarcoma
1
Plasma cell
1
Other hematologic neoplasm
1
Myeloid
1
Gynecologic
1
Dermatologic
1
CNS
1
Conditions
Breast Neoplasms
2
Carcinoma, Intraductal, Noninfiltrating
1
Carcinoma
1
Interventions
Letrozole
23
Docetaxel
17
Cyclophosphamide
13
Zoledronic Acid
12
Trastuzumab
12
Anastrozole
12
exemestane
11
Tamoxifen
11
Paclitaxel
11
Capecitabine
10
Fulvestrant
8
Epirubicin
8
pegfilgrastim
7
Saline Solution
7
Bupivacaine
7
pertuzumab
6
liposomal doxorubicin
6
abemaciclib
6
Sodium Chloride
6
Filgrastim
6
Carboplatin
6
pegylated granulocyte colony-stimulating factor
5
palbociclib
5
Ropivacaine
5
Dexmedetomidine
5
Bevacizumab
5
ribociclib
4
eribulin
4
Vinorelbine
4
Tranexamic Acid
4
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Phase 4
×
Radiotherapy
×
Breast
×
Clear all
NCT03948568
2022-09-30
REaCT-RETT
Ottawa Hospital Research Institute
Phase 4
Completed
262 enrolled
NCT00742222
2016-05-17
EXIBT
Xoft, Inc.
Phase 4
Completed
63 enrolled